Group 1 - Novartis was upgraded to Buy from Hold by Argus, with a price target set at $180, indicating a long-term pattern of higher highs and higher lows for the stock [1] - The stock's 14-day relative strength index dropped to 56, presenting an attractive entry point for healthcare investors following a recent pullback [1] - Novartis experienced strong demand across its portfolio, with product volumes increasing by 18% during the fourth quarter [2] Group 2 - The company's dividend was recently increased by 5.7% after shareholder approval, resulting in a yield of approximately 3.0%, which is considered an attractive component of the investment case [2] - The $180 price target implies a potential total return of roughly 15% from current levels when including dividend income [3]

Group 1 - AbbVie will announce its full-year and fourth-quarter 2025 financial results on February 4, 2026, before the market opens [1] - A live webcast of the earnings conference call will be hosted at 8 a.m. Central time, accessible through AbbVie's Investor Relations website [1] - An archived edition of the earnings call will be available later on the same day [1] Group 2 - AbbVie's mission focuses on discovering and delivering innovative medicines and solutions for serious health issues, addressing both current and future medical challenges [2] - The company aims to have a significant impact across key therapeutic areas, including immunology, oncology, neuroscience, and eye care, as well as in its Allergan Aesthetics portfolio [2] - Additional information about AbbVie can be found on its official website and social media platforms [2]